speb/financial-data huggingface dataset:
PCRX.V balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 4618148.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 20474082.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 2874532.00
PCRX.V income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: 222601.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 152492.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Working Capital: 13221012.00
PCRX.V income_statement (quarterly, 2025-06-30) — +Operating Expense: 2079126.00
PCRX.V income_statement (quarterly, 2025-06-30) — +Total Revenue: 4395709.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 1969064.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 643163.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Accumulated Depreciation: -145853.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 674733.00
PCRX.V income_statement (quarterly, 2025-06-30) — Basic Average Shares: 117295525.00
PCRX.V income_statement (quarterly, 2025-06-30) — Basic EPS: 0.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 12938515.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Buildings And Improvements: 3351341.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -2118535.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 522987.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Capital Stock: 31695204.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 9563682.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 9563682.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Cash Financial: 9563682.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: -50458.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: -3137549.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: -186826.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Change In Account Payable: 528421.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Change In Income Tax Payable: -131726.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Change In Inventory: -71043.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Change In Payable: 396695.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: 396695.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: -24311.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Change In Receivables: -270726.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Change In Tax Payable: -131726.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Change In Working Capital: 30615.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Changes In Account Receivables: -270726.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Changes In Cash: -3374833.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Common Stock: 31695204.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 30201625.00
PCRX.V income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 2647265.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Current Assets: 11955875.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 76184.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Current Debt: 75412.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 151596.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 2141426.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Deferred Income Tax: -33600.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Deferred Tax: -33600.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 188639.00
PCRX.V income_statement (quarterly, 2025-06-30) — Depreciation Amortization Depletion Income Statement: 188639.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 188639.00
PCRX.V income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 188639.00
PCRX.V income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 188639.00
PCRX.V income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 117295525.00
PCRX.V income_statement (quarterly, 2025-06-30) — Diluted EPS: 0.00
PCRX.V income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -384069.00
PCRX.V income_statement (quarterly, 2025-06-30) — EBIT: -214524.00
PCRX.V income_statement (quarterly, 2025-06-30) — EBITDA: -25885.00
PCRX.V cash_flow (quarterly, 2025-06-30) — End Cash Position: 9563682.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: -50458.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Free Cash Flow: -2305361.00
PCRX.V income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 1890487.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Goodwill: 12517969.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 19455620.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Gross PPE: 4105011.00
PCRX.V income_statement (quarterly, 2025-06-30) — Gross Profit: 1748444.00
PCRX.V income_statement (quarterly, 2025-06-30) — Interest Expense: 13245.00
PCRX.V income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 13245.00
PCRX.V income_statement (quarterly, 2025-06-30) — Interest Income: 83415.00
PCRX.V income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 83415.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Inventory: 1692566.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Invested Capital: 30557537.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -3137549.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Land And Improvements: 270275.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Leases: 309067.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 446803.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Long Term Debt: 280500.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 727303.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Long Term Debt Payments: -50458.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Machinery Furniture Equipment: 174328.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Minority Interest: 233213.00
PCRX.V income_statement (quarterly, 2025-06-30) — Minority Interests: 1656.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Net Business Purchase And Sale: -1019014.00
PCRX.V income_statement (quarterly, 2025-06-30) — Net Income: -384069.00
PCRX.V income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -384069.00
PCRX.V income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -385727.00
PCRX.V income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -384069.00
PCRX.V income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -384069.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: -385725.00
PCRX.V income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -385727.00
PCRX.V income_statement (quarterly, 2025-06-30) — Net Interest Income: 70170.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: -50458.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: -50458.00
PCRX.V income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: 70170.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Net PPE: 3959158.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -2118535.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 10746005.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Liabilities: 2067086.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Liabilities: 2067086.00
PCRX.V income_statement (quarterly, 2025-06-30) — Normalized EBITDA: -25885.00
PCRX.V income_statement (quarterly, 2025-06-30) — Normalized Income: -384069.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: -186826.00
PCRX.V income_statement (quarterly, 2025-06-30) — Operating Income: -330682.00
PCRX.V income_statement (quarterly, 2025-06-30) — Operating Revenue: 4337893.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 117295525.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Other Current Borrowings: 75412.00
PCRX.V income_statement (quarterly, 2025-06-30) — Other Gand A: 721086.00
PCRX.V income_statement (quarterly, 2025-06-30) — Other Income Expense: 32743.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Other Intangible Assets: 6937651.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: 13245.00
PCRX.V income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 32743.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Payables: 1989830.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 1989830.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Prepaid Assets: 56464.00
PCRX.V income_statement (quarterly, 2025-06-30) — Pretax Income: -227769.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Properties: 0.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Purchase Of Business: -1019014.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -2118535.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Receivables: 643163.00
PCRX.V income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 2647265.00
PCRX.V income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 188639.00
PCRX.V cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: -50458.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -2168312.00
PCRX.V income_statement (quarterly, 2025-06-30) — Salaries And Wages: 1169401.00
PCRX.V income_statement (quarterly, 2025-06-30) — Selling General And Administration: 1890487.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Share Issued: 117295525.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 30201625.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 10746005.00
PCRX.V income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
PCRX.V income_statement (quarterly, 2025-06-30) — Tax Provision: 157958.00
PCRX.V income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.15
PCRX.V balance_sheet (quarterly, 2025-06-30) — Total Assets: 35370653.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 30482125.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Total Debt: 878899.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 30434838.00
PCRX.V income_statement (quarterly, 2025-06-30) — Total Expenses: 4726391.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 4935815.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 23414778.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 2794389.00
PCRX.V income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: -336032.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Total Tax Payable: 20766.00
PCRX.V balance_sheet (quarterly, 2025-06-30) — Working Capital: 9814449.00
PCRX.V income_statement (quarterly, 2025-09-30) — +Operating Expense: 2457776.00
PCRX.V income_statement (quarterly, 2025-09-30) — +Total Revenue: 4802259.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 2840588.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 785928.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Accumulated Depreciation: -195834.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 879801.00
PCRX.V income_statement (quarterly, 2025-09-30) — Basic Average Shares: 117295525.00
PCRX.V income_statement (quarterly, 2025-09-30) — Basic EPS: 0.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 9563682.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Buildings And Improvements: 3591717.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 768364.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Capital Stock: 31695204.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 5024801.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 5024801.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Cash Financial: 5024801.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: 3083552.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -8172692.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 550259.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Change In Account Payable: 829679.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Change In Income Tax Payable: 0.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Change In Inventory: -324865.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Change In Payable: 829679.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 829679.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: -131205.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Change In Receivables: 185785.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Change In Tax Payable: 0.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Change In Working Capital: 559394.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Changes In Account Receivables: 185785.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Changes In Cash: -4538881.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Common Stock: 31695204.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 29979175.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Common Stock Issuance: 0.00
PCRX.V income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 2843299.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Current Assets: 8463147.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 88475.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Current Debt: 404682.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 493157.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 3344699.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Deferred Income Tax: -47158.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Deferred Tax: -47158.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 222331.00
PCRX.V income_statement (quarterly, 2025-09-30) — Depreciation Amortization Depletion Income Statement: 222331.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 222331.00
PCRX.V income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 222331.00
PCRX.V income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 222331.00
PCRX.V income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 117295525.00
PCRX.V income_statement (quarterly, 2025-09-30) — Diluted EPS: 0.00
PCRX.V income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -427516.00
PCRX.V income_statement (quarterly, 2025-09-30) — EBIT: -408277.00
PCRX.V income_statement (quarterly, 2025-09-30) — EBITDA: -185946.00
PCRX.V cash_flow (quarterly, 2025-09-30) — End Cash Position: 5024801.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: 3083552.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 2627449.00
PCRX.V income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 2235445.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Goodwill: 14028756.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 21982454.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Gross PPE: 4426280.00
PCRX.V income_statement (quarterly, 2025-09-30) — Gross Profit: 1958960.00
PCRX.V income_statement (quarterly, 2025-09-30) — Interest Expense: 19803.00
PCRX.V income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 19803.00
PCRX.V income_statement (quarterly, 2025-09-30) — Interest Income: 56182.00
PCRX.V income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 56182.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Inventory: 2464249.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Invested Capital: 33529712.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -8172692.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Issuance Of Capital Stock: 0.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Land And Improvements: 270275.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Leases: 309067.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 679889.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 3145855.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 3825744.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: -61020.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Machinery Furniture Equipment: 255221.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Minority Interest: 233336.00
PCRX.V income_statement (quarterly, 2025-09-30) — Minority Interests: -18339.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Net Business Purchase And Sale: -10249882.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: 0.00
PCRX.V income_statement (quarterly, 2025-09-30) — Net Income: -427516.00
PCRX.V income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -427516.00
PCRX.V income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -409178.00
PCRX.V income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -427516.00
PCRX.V income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -427516.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -409179.00
PCRX.V income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -409178.00
PCRX.V income_statement (quarterly, 2025-09-30) — Net Interest Income: 36379.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: 3101768.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: 3101768.00
PCRX.V income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 36379.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Net PPE: 4230446.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: 2077190.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 7996721.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 2328123.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 2328123.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Non Current Prepaid Assets: 5035030.00
PCRX.V income_statement (quarterly, 2025-09-30) — Normalized EBITDA: -185946.00
PCRX.V income_statement (quarterly, 2025-09-30) — Normalized Income: -427516.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 550259.00
PCRX.V income_statement (quarterly, 2025-09-30) — Operating Income: -498816.00
PCRX.V income_statement (quarterly, 2025-09-30) — Operating Revenue: 4749478.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 117295525.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Other Current Borrowings: 404682.00
PCRX.V income_statement (quarterly, 2025-09-30) — Other Gand A: 901996.00
PCRX.V income_statement (quarterly, 2025-09-30) — Other Income Expense: 34357.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 7953698.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Other Inventories: 2410928.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: 19803.00
PCRX.V income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 34357.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Payables: 2851542.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 2851542.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Prepaid Assets: 188169.00
PCRX.V income_statement (quarterly, 2025-09-30) — Pretax Income: -428080.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: 0.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Properties: 0.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Purchase Of Business: -10249882.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: 2077190.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Raw Materials: 53321.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Receivables: 785928.00
PCRX.V income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 2843299.00
PCRX.V income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 222331.00
PCRX.V cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: -61020.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -2595830.00
PCRX.V income_statement (quarterly, 2025-09-30) — Salaries And Wages: 1333449.00
PCRX.V income_statement (quarterly, 2025-09-30) — Selling General And Administration: 2235445.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Share Issued: 117295525.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 29979175.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 7996721.00
PCRX.V income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
PCRX.V income_statement (quarterly, 2025-09-30) — Tax Provision: -18902.00
PCRX.V income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.04
PCRX.V balance_sheet (quarterly, 2025-09-30) — Total Assets: 39711077.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 33125030.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Total Debt: 4318901.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 30212511.00
PCRX.V income_statement (quarterly, 2025-09-30) — Total Expenses: 5301075.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 9498566.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 31247930.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 6153867.00
PCRX.V income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: -508223.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 10954.00
PCRX.V balance_sheet (quarterly, 2025-09-30) — Working Capital: 5118448.00
PCRX.V income_statement (annual, 2025-12-31) — +Operating Expense: 9535965.00
PCRX.V income_statement (quarterly, 2025-12-31) — +Operating Expense: 3603212.00
PCRX.V income_statement (annual, 2025-12-31) — +Total Revenue: 20894507.00
PCRX.V income_statement (quarterly, 2025-12-31) — +Total Revenue: 7689580.00
PCRX.V balance_sheet (annual, 2025-12-31) — Accounts Payable: 5202824.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 5202824.00
PCRX.V balance_sheet (annual, 2025-12-31) — Accounts Receivable: 1217955.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 1217955.00
PCRX.V balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -235672.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -235672.00
PCRX.V balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 2006612.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 2006612.00
PCRX.V income_statement (annual, 2025-12-31) — Basic Average Shares: 125138642.00
PCRX.V income_statement (annual, 2025-12-31) — Basic EPS: -0.01
PCRX.V cash_flow (annual, 2025-12-31) — Beginning Cash Position: 12886556.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 5024801.00
PCRX.V balance_sheet (annual, 2025-12-31) — Buildings And Improvements: 4728159.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Buildings And Improvements: 4728159.00
PCRX.V cash_flow (annual, 2025-12-31) — Capital Expenditure: -2177602.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -2109354.00
PCRX.V balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 1064490.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 1064490.00
PCRX.V balance_sheet (annual, 2025-12-31) — Capital Stock: 50951503.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Capital Stock: 50951503.00
PCRX.V balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 25885295.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 25885295.00
PCRX.V balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 25885295.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 25885295.00
PCRX.V balance_sheet (annual, 2025-12-31) — Cash Financial: 25885295.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Cash Financial: 25885295.00
PCRX.V cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: 24709857.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 21727435.00
PCRX.V cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: -13717485.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -2380341.00
PCRX.V cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: 2006367.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: 1513400.00
PCRX.V cash_flow (annual, 2025-12-31) — Change In Account Payable: 2270505.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Change In Account Payable: 1008030.00
PCRX.V cash_flow (annual, 2025-12-31) — Change In Income Tax Payable: 264722.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Change In Income Tax Payable: 254477.00
PCRX.V cash_flow (annual, 2025-12-31) — Change In Inventory: -314316.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Change In Inventory: 390076.00
PCRX.V cash_flow (annual, 2025-12-31) — Change In Payable: 2535227.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Change In Payable: 1262507.00
PCRX.V cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: 2535227.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 1262507.00
PCRX.V cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: -25224.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: 114419.00
PCRX.V cash_flow (annual, 2025-12-31) — Change In Receivables: -70368.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Change In Receivables: 60227.00
PCRX.V cash_flow (annual, 2025-12-31) — Change In Tax Payable: 264722.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Change In Tax Payable: 254477.00
PCRX.V cash_flow (annual, 2025-12-31) — Change In Working Capital: 2125319.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Change In Working Capital: 1827229.00
PCRX.V cash_flow (annual, 2025-12-31) — Changes In Account Receivables: -141846.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Changes In Account Receivables: -11251.00
PCRX.V cash_flow (annual, 2025-12-31) — Changes In Cash: 12998739.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Changes In Cash: 20860494.00
PCRX.V balance_sheet (annual, 2025-12-31) — Common Stock: 50951503.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Common Stock: 50951503.00
PCRX.V balance_sheet (annual, 2025-12-31) — Common Stock Equity: 51921980.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 51921980.00
PCRX.V cash_flow (annual, 2025-12-31) — Common Stock Issuance: 21438272.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Common Stock Issuance: 21438272.00
PCRX.V income_statement (annual, 2025-12-31) — Cost Of Revenue: 12596234.00
PCRX.V income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 4722729.00
PCRX.V balance_sheet (annual, 2025-12-31) — Current Assets: 29889257.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Current Assets: 29889257.00
PCRX.V balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 152786.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 152786.00
PCRX.V balance_sheet (annual, 2025-12-31) — Current Debt: 391691.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Current Debt: 391691.00
PCRX.V balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 544477.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 544477.00
PCRX.V balance_sheet (annual, 2025-12-31) — Current Liabilities: 5809769.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 5809769.00
PCRX.V cash_flow (annual, 2025-12-31) — Deferred Income Tax: -142431.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Deferred Income Tax: -27662.00
PCRX.V cash_flow (annual, 2025-12-31) — Deferred Tax: -142431.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Deferred Tax: -27662.00
PCRX.V cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 940196.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 341767.00
PCRX.V income_statement (annual, 2025-12-31) — Depreciation Amortization Depletion Income Statement: 940196.00
PCRX.V income_statement (quarterly, 2025-12-31) — Depreciation Amortization Depletion Income Statement: 341767.00
PCRX.V cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 940196.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 341767.00
PCRX.V income_statement (annual, 2025-12-31) — Depreciation And Amortization In Income Statement: 940196.00
PCRX.V income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 341767.00
PCRX.V income_statement (annual, 2025-12-31) — Depreciation Income Statement: 940196.00
PCRX.V income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 743856.00
PCRX.V income_statement (annual, 2025-12-31) — Diluted Average Shares: 125138642.00
PCRX.V income_statement (annual, 2025-12-31) — Diluted EPS: -0.01
PCRX.V income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -1422057.00
PCRX.V income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -852383.00
PCRX.V income_statement (annual, 2025-12-31) — EBIT: -736123.00
PCRX.V income_statement (quarterly, 2025-12-31) — EBIT: -489058.00
PCRX.V income_statement (annual, 2025-12-31) — EBITDA: 204073.00
PCRX.V income_statement (quarterly, 2025-12-31) — EBITDA: -147291.00
PCRX.V cash_flow (annual, 2025-12-31) — End Cash Position: 25885295.00
PCRX.V cash_flow (quarterly, 2025-12-31) — End Cash Position: 25885295.00
PCRX.V cash_flow (annual, 2025-12-31) — Financing Cash Flow: 24709857.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 21727435.00
PCRX.V cash_flow (annual, 2025-12-31) — Free Cash Flow: -171235.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Free Cash Flow: -595954.00
PCRX.V income_statement (annual, 2025-12-31) — General And Administrative Expense: 8595769.00
PCRX.V income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 3261445.00
PCRX.V balance_sheet (annual, 2025-12-31) — Goodwill: 18599223.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Goodwill: 18599223.00
PCRX.V balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 30199970.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 30199970.00
PCRX.V balance_sheet (annual, 2025-12-31) — Gross PPE: 5716728.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Gross PPE: 5716728.00
PCRX.V income_statement (annual, 2025-12-31) — Gross Profit: 8298273.00
PCRX.V income_statement (quarterly, 2025-12-31) — Gross Profit: 2966851.00
PCRX.V income_statement (annual, 2025-12-31) — Interest Expense: 99677.00
PCRX.V income_statement (quarterly, 2025-12-31) — Interest Expense: 52923.00
PCRX.V income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 99677.00
PCRX.V income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 52923.00
PCRX.V income_statement (annual, 2025-12-31) — Interest Income: 293958.00
PCRX.V income_statement (quarterly, 2025-12-31) — Interest Income: 50033.00
PCRX.V income_statement (annual, 2025-12-31) — Interest Income Non Operating: 293958.00
PCRX.V income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 50033.00
PCRX.V balance_sheet (annual, 2025-12-31) — Inventory: 2705153.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Inventory: 2705153.00
PCRX.V balance_sheet (annual, 2025-12-31) — Invested Capital: 55402974.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Invested Capital: 55402974.00
PCRX.V cash_flow (annual, 2025-12-31) — Investing Cash Flow: -13717485.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -2380341.00
PCRX.V cash_flow (annual, 2025-12-31) — Issuance Of Capital Stock: 21438272.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Issuance Of Capital Stock: 21438272.00
PCRX.V cash_flow (annual, 2025-12-31) — Issuance Of Debt: 3162788.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Issuance Of Debt: 0.00
PCRX.V balance_sheet (annual, 2025-12-31) — Land And Improvements: 384125.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Land And Improvements: 384125.00
PCRX.V balance_sheet (annual, 2025-12-31) — Leases: 314276.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Leases: 314276.00
PCRX.V balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 911704.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 911704.00
PCRX.V balance_sheet (annual, 2025-12-31) — Long Term Debt: 3089303.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Long Term Debt: 3089303.00
PCRX.V balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 4001007.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 4001007.00
PCRX.V cash_flow (annual, 2025-12-31) — Long Term Debt Issuance: 3162788.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Long Term Debt Issuance: 0.00
PCRX.V cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -322987.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: -160837.00
PCRX.V balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 290168.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 290168.00
PCRX.V balance_sheet (annual, 2025-12-31) — Minority Interest: 347946.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Minority Interest: 347946.00
PCRX.V cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: -11539883.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Net Business Purchase And Sale: -270987.00
PCRX.V cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: 21438272.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: 21438272.00
PCRX.V income_statement (annual, 2025-12-31) — Net Income: -1422057.00
PCRX.V income_statement (quarterly, 2025-12-31) — Net Income: -852383.00
PCRX.V income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -1422057.00
PCRX.V income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -852383.00
PCRX.V income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -1422057.00
PCRX.V income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -881453.00
PCRX.V income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -1422057.00
PCRX.V income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -852383.00
PCRX.V income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -1422057.00
PCRX.V income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -852383.00
PCRX.V cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: -1422057.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -881452.00
PCRX.V income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -1422057.00
PCRX.V income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -881453.00
PCRX.V income_statement (annual, 2025-12-31) — Net Interest Income: 194281.00
PCRX.V income_statement (quarterly, 2025-12-31) — Net Interest Income: -2890.00
PCRX.V cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: 2839801.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: -160837.00
PCRX.V cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: 2839801.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: -160837.00
PCRX.V income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: 194281.00
PCRX.V income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -2890.00
PCRX.V cash_flow (annual, 2025-12-31) — Net Other Financing Charges: 431784.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: 450000.00
PCRX.V balance_sheet (annual, 2025-12-31) — Net PPE: 5481056.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Net PPE: 5481056.00
PCRX.V cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -2177602.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: -2109354.00
PCRX.V balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 21722010.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 21722010.00
PCRX.V balance_sheet (annual, 2025-12-31) — Non Current Deferred Liabilities: 3489581.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Liabilities: 3489581.00
PCRX.V balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 3489581.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 3489581.00
PCRX.V income_statement (annual, 2025-12-31) — Normalized EBITDA: 204073.00
PCRX.V income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -147291.00
PCRX.V income_statement (annual, 2025-12-31) — Normalized Income: -1422057.00
PCRX.V income_statement (quarterly, 2025-12-31) — Normalized Income: -852383.00
PCRX.V cash_flow (annual, 2025-12-31) — Operating Cash Flow: 2006367.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: 1513400.00
PCRX.V income_statement (annual, 2025-12-31) — Operating Income: -1237692.00
PCRX.V income_statement (quarterly, 2025-12-31) — Operating Income: -636361.00
PCRX.V income_statement (annual, 2025-12-31) — Operating Revenue: 20649384.00
PCRX.V income_statement (quarterly, 2025-12-31) — Operating Revenue: 7595122.00
PCRX.V balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 174081659.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 174081659.00
PCRX.V balance_sheet (annual, 2025-12-31) — Other Current Borrowings: 391691.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Other Current Borrowings: 391691.00
PCRX.V balance_sheet (annual, 2025-12-31) — Other Equity Interest: 2105757.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Other Equity Interest: 2105757.00
PCRX.V income_statement (annual, 2025-12-31) — Other Gand A: 3312144.00
PCRX.V income_statement (quarterly, 2025-12-31) — Other Gand A: 1309301.00
PCRX.V income_statement (annual, 2025-12-31) — Other Income Expense: 207611.00
PCRX.V income_statement (quarterly, 2025-12-31) — Other Income Expense: 97270.00
PCRX.V balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 11600747.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 11600747.00
PCRX.V balance_sheet (annual, 2025-12-31) — Other Inventories: 2657518.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Other Inventories: 2657518.00
PCRX.V cash_flow (annual, 2025-12-31) — Other Non Cash Items: 99677.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 52923.00
PCRX.V income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: 207611.00
PCRX.V income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 97270.00
PCRX.V balance_sheet (annual, 2025-12-31) — Payables: 5265292.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Payables: 5265292.00
PCRX.V balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 5265292.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 5265292.00
PCRX.V balance_sheet (annual, 2025-12-31) — Prepaid Assets: 80854.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 80854.00
PCRX.V income_statement (annual, 2025-12-31) — Pretax Income: -835800.00
PCRX.V income_statement (quarterly, 2025-12-31) — Pretax Income: -541981.00
PCRX.V cash_flow (annual, 2025-12-31) — Proceeds From Stock Option Exercised: 0.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 0.00
PCRX.V balance_sheet (annual, 2025-12-31) — Properties: 0.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
PCRX.V cash_flow (annual, 2025-12-31) — Purchase Of Business: -11539883.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Purchase Of Business: -270987.00
PCRX.V cash_flow (annual, 2025-12-31) — Purchase Of PPE: -2177602.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: -2109354.00
PCRX.V balance_sheet (annual, 2025-12-31) — Raw Materials: 47635.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Raw Materials: 47635.00
PCRX.V balance_sheet (annual, 2025-12-31) — Receivables: 1217955.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Receivables: 1217955.00
PCRX.V income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 12596234.00
PCRX.V income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 4722729.00
PCRX.V income_statement (annual, 2025-12-31) — Reconciled Depreciation: 940196.00
PCRX.V income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 341767.00
PCRX.V cash_flow (annual, 2025-12-31) — Repayment Of Debt: -322987.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: -160837.00
PCRX.V balance_sheet (annual, 2025-12-31) — Retained Earnings: -3141892.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -3141892.00
PCRX.V income_statement (annual, 2025-12-31) — Salaries And Wages: 5283625.00
PCRX.V income_statement (quarterly, 2025-12-31) — Salaries And Wages: 1952144.00
PCRX.V income_statement (annual, 2025-12-31) — Selling General And Administration: 8595769.00
PCRX.V income_statement (quarterly, 2025-12-31) — Selling General And Administration: 3261445.00
PCRX.V balance_sheet (annual, 2025-12-31) — Share Issued: 174081659.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Share Issued: 174081659.00
PCRX.V cash_flow (annual, 2025-12-31) — Stock Based Compensation: 405663.00
PCRX.V cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 200595.00
PCRX.V balance_sheet (annual, 2025-12-31) — Stockholders Equity: 51921980.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 51921980.00
PCRX.V balance_sheet (annual, 2025-12-31) — Tangible Book Value: 21722010.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 21722010.00
PCRX.V income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
PCRX.V income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
PCRX.V income_statement (annual, 2025-12-31) — Tax Provision: 586257.00
PCRX.V income_statement (quarterly, 2025-12-31) — Tax Provision: 339472.00
PCRX.V income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.15
PCRX.V income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.15
PCRX.V balance_sheet (annual, 2025-12-31) — Total Assets: 65570283.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Total Assets: 65570283.00
PCRX.V balance_sheet (annual, 2025-12-31) — Total Capitalization: 55011283.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 55011283.00
PCRX.V balance_sheet (annual, 2025-12-31) — Total Debt: 4545484.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Total Debt: 4545484.00
PCRX.V balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 52269926.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 52269926.00
PCRX.V income_statement (annual, 2025-12-31) — Total Expenses: 22132199.00
PCRX.V income_statement (quarterly, 2025-12-31) — Total Expenses: 8325941.00
PCRX.V balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 13300357.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 13300357.00
PCRX.V balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 35681026.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 35681026.00
PCRX.V balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 7490588.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 7490588.00
PCRX.V income_statement (annual, 2025-12-31) — Total Operating Income As Reported: -1294557.00
PCRX.V income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: -672900.00
PCRX.V balance_sheet (annual, 2025-12-31) — Total Tax Payable: 62468.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Total Tax Payable: 62468.00
PCRX.V balance_sheet (annual, 2025-12-31) — Working Capital: 24079488.00
PCRX.V balance_sheet (quarterly, 2025-12-31) — Working Capital: 24079488.00
PCRX.V income_statement (quarterly, 2026-03-31) — +Operating Expense: 2843490.00
PCRX.V income_statement (quarterly, 2026-03-31) — +Total Revenue: 7188412.00
PCRX.V balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 2380891.00
PCRX.V balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 1184537.00
PCRX.V balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -304243.00
PCRX.V balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 2061945.00
PCRX.V income_statement (quarterly, 2026-03-31) — Amortization: 238521.00
PCRX.V cash_flow (quarterly, 2026-03-31) — Amortization Cash Flow: 238521.00
PCRX.V cash_flow (quarterly, 2026-03-31) — Amortization Of Intangibles: 238521.00
PCRX.V income_statement (quarterly, 2026-03-31) — Amortization Of Intangibles Income Statement: 238521.00
PCRX.V income_statement (quarterly, 2026-03-31) — Basic Average Shares: 174081659.00
PCRX.V income_statement (quarterly, 2026-03-31) — Basic EPS: 0.00
PCRX.V cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 25885295.00
PCRX.V balance_sheet (quarterly, 2026-03-31) — Buildings And Improvements: 4670767.00
PCRX.V cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -85407.00
PCRX.V balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 1014340.00
PCRX.V balance_sheet (quarterly, 2026-03-31) — Capital Stock: 50951503.00
PCRX.V balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 23380561.00
PCRX.V balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 23380561.00
PCRX.V balance_sheet (quarterly, 2026-03-31) — Cash Financial: 23380561.00
PCRX.V cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 267982.00
PCRX.V cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -103056.00
PCRX.V cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -2669660.00
PCRX.V cash_flow (quarterly, 2026-03-31) — Change In Account Payable: -2821933.00
PCRX.V cash_flow (quarterly, 2026-03-31) — Change In Income Tax Payable: -42191.00
PCRX.V cash_flow (quarterly, 2026-03-31) — Change In Inventory: -347970.00
PCRX.V cash_flow (quarterly, 2026-03-31) — Change In Payable: -2864124.00
PCRX.V cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: -2864124.00
PCRX.V cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: -12960.00
PCRX.V cash_flow (quarterly, 2026-03-31) — Change In Receivables: 33418.00
PCRX.V cash_flow (quarterly, 2026-03-31) — Change In Tax Payable: -42191.00
PCRX.V cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -3191636.00
PCRX.V cash_flow (quarterly, 2026-03-31) — Changes In Account Receivables: 33418.00
PCRX.V cash_flow (quarterly, 2026-03-31) — Changes In Cash: -2504734.00